Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ataxia | 7 | 2020 | 79 | 3.940 |
Why?
|
| Fragile X Syndrome | 8 | 2020 | 190 | 3.830 |
Why?
|
| Tremor | 7 | 2020 | 141 | 3.770 |
Why?
|
| Postural Balance | 4 | 2021 | 124 | 1.460 |
Why?
|
| Gait | 6 | 2020 | 407 | 1.380 |
Why?
|
| Fragile X Mental Retardation Protein | 5 | 2016 | 117 | 1.360 |
Why?
|
| Accidental Falls | 3 | 2020 | 114 | 1.350 |
Why?
|
| Gait Disorders, Neurologic | 3 | 2020 | 144 | 1.270 |
Why?
|
| Heterozygote | 4 | 2020 | 107 | 1.200 |
Why?
|
| Walking Speed | 2 | 2020 | 43 | 0.840 |
Why?
|
| Psychomotor Performance | 2 | 2020 | 218 | 0.810 |
Why?
|
| Databases, Factual | 2 | 2021 | 354 | 0.800 |
Why?
|
| Walking | 2 | 2022 | 258 | 0.780 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.700 |
Why?
|
| Nootropic Agents | 1 | 2020 | 12 | 0.700 |
Why?
|
| Attention | 1 | 2020 | 145 | 0.670 |
Why?
|
| Huntington Disease | 1 | 2020 | 57 | 0.660 |
Why?
|
| Movement Disorders | 2 | 2020 | 118 | 0.650 |
Why?
|
| Phenotype | 3 | 2016 | 379 | 0.640 |
Why?
|
| Cyclodextrins | 1 | 2018 | 9 | 0.600 |
Why?
|
| Male | 17 | 2021 | 16499 | 0.600 |
Why?
|
| Executive Function | 1 | 2018 | 125 | 0.590 |
Why?
|
| Niemann-Pick Disease, Type C | 1 | 2018 | 24 | 0.590 |
Why?
|
| Female | 16 | 2021 | 17018 | 0.560 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 1133 | 0.550 |
Why?
|
| Receptors, Estrogen | 5 | 1995 | 70 | 0.460 |
Why?
|
| Hyperkinesis | 1 | 2013 | 9 | 0.450 |
Why?
|
| Humans | 16 | 2022 | 31070 | 0.450 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 20 | 0.450 |
Why?
|
| Middle Aged | 9 | 2020 | 10239 | 0.440 |
Why?
|
| Aged | 9 | 2022 | 10079 | 0.440 |
Why?
|
| Adolescent | 4 | 2021 | 2403 | 0.410 |
Why?
|
| Cognition Disorders | 1 | 2018 | 1055 | 0.380 |
Why?
|
| Neuropsychological Tests | 4 | 2020 | 1316 | 0.360 |
Why?
|
| Biomechanical Phenomena | 4 | 2022 | 699 | 0.360 |
Why?
|
| Reference Values | 2 | 2021 | 229 | 0.360 |
Why?
|
| Walk Test | 2 | 2020 | 10 | 0.350 |
Why?
|
| Child | 3 | 2021 | 1431 | 0.350 |
Why?
|
| Child, Preschool | 2 | 2021 | 691 | 0.320 |
Why?
|
| Adult | 5 | 2021 | 8949 | 0.320 |
Why?
|
| Young Adult | 3 | 2021 | 2063 | 0.310 |
Why?
|
| Hippocampus | 4 | 1995 | 280 | 0.310 |
Why?
|
| Cognition | 3 | 2020 | 1427 | 0.250 |
Why?
|
| Parkinson Disease | 3 | 2020 | 1069 | 0.240 |
Why?
|
| Shoes | 1 | 2022 | 30 | 0.200 |
Why?
|
| Case-Control Studies | 2 | 2020 | 663 | 0.190 |
Why?
|
| Pilot Projects | 2 | 2020 | 429 | 0.190 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 4 | 0.180 |
Why?
|
| Time and Motion Studies | 1 | 2020 | 18 | 0.180 |
Why?
|
| Foot | 1 | 2020 | 32 | 0.180 |
Why?
|
| Glucosylceramidase | 1 | 2020 | 26 | 0.170 |
Why?
|
| Retrospective Studies | 2 | 2020 | 3665 | 0.170 |
Why?
|
| Arm | 1 | 2020 | 82 | 0.170 |
Why?
|
| Range of Motion, Articular | 2 | 2020 | 736 | 0.160 |
Why?
|
| Infusions, Spinal | 1 | 2018 | 6 | 0.150 |
Why?
|
| Mutation | 1 | 2020 | 409 | 0.150 |
Why?
|
| Spinal Puncture | 1 | 2018 | 30 | 0.150 |
Why?
|
| Animals | 7 | 2016 | 4724 | 0.140 |
Why?
|
| Motor Activity | 1 | 2020 | 370 | 0.140 |
Why?
|
| Brain Tissue Transplantation | 2 | 1993 | 21 | 0.140 |
Why?
|
| Congresses as Topic | 1 | 2016 | 32 | 0.140 |
Why?
|
| Posture | 1 | 2016 | 72 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 5192 | 0.130 |
Why?
|
| Computers | 1 | 2015 | 27 | 0.130 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2015 | 46 | 0.130 |
Why?
|
| Early Diagnosis | 1 | 2015 | 69 | 0.130 |
Why?
|
| Animals, Newborn | 3 | 1993 | 59 | 0.130 |
Why?
|
| Reaction Time | 1 | 2015 | 128 | 0.130 |
Why?
|
| Time Factors | 1 | 2020 | 1681 | 0.130 |
Why?
|
| Neuroimaging | 1 | 2016 | 144 | 0.130 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 95 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2015 | 300 | 0.120 |
Why?
|
| Sexual Behavior, Animal | 1 | 1994 | 4 | 0.120 |
Why?
|
| Pituitary-Adrenal System | 1 | 1994 | 12 | 0.120 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1994 | 13 | 0.120 |
Why?
|
| Receptors, Progesterone | 1 | 1994 | 33 | 0.120 |
Why?
|
| Arousal | 1 | 1994 | 44 | 0.120 |
Why?
|
| Cerebral Cortex | 2 | 1993 | 195 | 0.120 |
Why?
|
| Disability Evaluation | 1 | 2016 | 333 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 1995 | 329 | 0.120 |
Why?
|
| Task Performance and Analysis | 1 | 2013 | 53 | 0.110 |
Why?
|
| Cerebellar Diseases | 1 | 2013 | 7 | 0.110 |
Why?
|
| Disease Progression | 1 | 2016 | 830 | 0.110 |
Why?
|
| Rats | 6 | 1995 | 873 | 0.110 |
Why?
|
| Movement | 1 | 2013 | 137 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 551 | 0.100 |
Why?
|
| Neurons | 2 | 1995 | 378 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2016 | 2045 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 1314 | 0.090 |
Why?
|
| Treatment Outcome | 1 | 2020 | 3809 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 1209 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1995 | 468 | 0.050 |
Why?
|
| Fetal Tissue Transplantation | 2 | 1993 | 25 | 0.050 |
Why?
|
| Estradiol | 2 | 1993 | 46 | 0.050 |
Why?
|
| Mechanical Phenomena | 1 | 2022 | 24 | 0.050 |
Why?
|
| Pregnancy | 2 | 1993 | 405 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 818 | 0.040 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 1995 | 1 | 0.030 |
Why?
|
| N-Methylaspartate | 1 | 1995 | 4 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1995 | 22 | 0.030 |
Why?
|
| Receptors, AMPA | 1 | 1995 | 14 | 0.030 |
Why?
|
| Sex Differentiation | 1 | 1995 | 2 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1995 | 27 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1995 | 28 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1995 | 52 | 0.030 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 1994 | 8 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1994 | 9 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1992 | 31 | 0.030 |
Why?
|
| Cytosol | 2 | 1992 | 63 | 0.030 |
Why?
|
| Gene Expression | 1 | 1995 | 239 | 0.030 |
Why?
|
| Transplantation, Heterotopic | 1 | 1993 | 8 | 0.030 |
Why?
|
| Preoptic Area | 1 | 1993 | 6 | 0.030 |
Why?
|
| Brain Mapping | 1 | 1994 | 190 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 1993 | 83 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1008 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 1994 | 287 | 0.030 |
Why?
|
| Age Factors | 1 | 1995 | 874 | 0.030 |
Why?
|
| Aging | 2 | 1993 | 1727 | 0.020 |
Why?
|
| Calcium | 1 | 1995 | 503 | 0.020 |
Why?
|
| Diethylstilbestrol | 1 | 1990 | 1 | 0.020 |
Why?
|
| Ethinyl Estradiol | 1 | 1990 | 2 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 1990 | 3 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 1990 | 9 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1990 | 80 | 0.020 |
Why?
|
| Kinetics | 1 | 1990 | 228 | 0.020 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 1095 | 0.020 |
Why?
|
| Sex Factors | 1 | 1990 | 510 | 0.020 |
Why?
|
| Receptors, Glutamate | 1 | 1995 | 5 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 1995 | 33 | 0.010 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1995 | 34 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1995 | 686 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1992 | 296 | 0.010 |
Why?
|